Stay updated with breaking news from Wouter Piepers. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.
Leuven, BE, Boston, MA, US - April 13th, 2021 - 7.30 AM CET - Oxurion NV(Euronext Brussels: OXUR), a biopharmaceutical company developing next generation standard-of-care ophthalmic therapies, with a clinical
Press release content from Globe Newswire. The AP news staff was not involved in its creation. Oncurious NV Reports Encouraging Data from Phase 1 Dose Escalation Study of TB-403 in ... Oxurion NVApril 12, 2021 GMT Leuven, Belgium, Boston, MA, US, 12 April 2021 – 7.30 AM CET – ONCURIOUS NV, a Belgium-based biotech company focused on developing innovative oncology treatments, today announces that encouraging data from a Phase 1 dose escalation study of TB-403 in pediatric subjects with relapsed or refractory medulloblastoma (MB), was presented at the annual meeting of the American Associat...
Press release content from Globe Newswire. The AP news staff was not involved in its creation. ONCURIOUS Presenting Clinical and Preclinical Data at Upcoming American Association for Cancer ... Oxurion NVApril 9, 2021 GMT Oral presentation of Phase 1 dose escalation study of TB-403 in pediatric subjects with relapsed or refractory medulloblastoma (MB) Poster presentation of research findings of best therapeutic approach to target CCR8 expressed on tumor regulatory T cells to boost anti-tumor immune responses Leuven, Belgium 9th April 2021 – 7.30 AM CET – ONCURIOUS NV, a Belgium-based b...
Oxurion NV – Publication in Progress in Retinal Eye Research highlights the potential of pan-RGD integrin antagonists to improve the treatment of diabetic retinopathy and wet AMD 04/07/2021 | 11:45am EDT Send by mail : Message : Required fields Oxurion is a leader in the development of pan-RGD integrin antagonists for retinal vascular disorders - THR-687 on track to enter Phase 2 development by mid-year Leuven, BE, Boston, MA, US – April 7, 2021 – 05.45 PM CET – Oxurion NV (Euronext Brussels: OXUR), a biopharmaceutical company developing next generation standard-of-care therapies for ...
Oxurion NV - Publication in Progress in Retinal Eye Research highlights the potential of pan-RGD integrin antagonists to improve the treatment of diabetic retinopathy and wet AMD & Corporate Communications wouter.piepers@oxurion.com (mailto:wouter.piepers@oxurion.com) EU Tel: +44 20 7638 9571 oxurion@citigatedewerogerson.com (mailto:thrombogenics@citigatedewerogerson.com) US chris.brinzey@westwicke.com (mailto:chris.brinzey@westwicke.com) About Oxurion Oxurion (Euronext Brussels: OXUR) is a biopharmaceutical company developing next generation standard of care ophthalmic therapies, which are...